
<p>The Immunostimulative Effect and Mechanisms of a Novel Mouse Anti-Human PD-1 Monoclonal Antibody on Jurkat Lymphocytic Cells Cocultured with Hepatoma Cells</p>
Author(s) -
Ziwei Li,
Bin Li,
Li Li,
Guanying Wang,
Yuanyuan Li,
Ruoqiu Fu,
Yue Ming,
Rui Ni,
Jiming Wang,
George Ye,
Jianhong Chen
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s281397
Subject(s) - jurkat cells , apoptosis , monoclonal antibody , cell culture , microbiology and biotechnology , cancer cell , t cell , cell cycle , biology , cancer research , immune system , chemistry , antibody , immunology , cancer , biochemistry , genetics
Monoclonal antibodies (mAbs) that target the programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint have demonstrated substantial clinical benefit for a variety of solid tumors. However, their applications in patients with hepatocellular carcinoma (HCC) are reported with unclear molecular mechanisms. Here, we report a novel mouse anti-human PD-1 mAb that can reverse the immunosuppressive effect of HePG2 cells on Jurkat cells.